FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
Fuente:
FierceBiotech
The FDA is ending a roughly nine-month hiatus of drug-related advisory committee meetings, convening its first session of 2026 to scrutinize a pair of oncology applications from AstraZeneca.